A made-in-Canada treatment for Alzheimer’s disease could be closer to patients thanks to a new technology developed by Faculty of Medicine neuroscientist Neil Cashman. Cashman, professor in the Division of Neurology at UBC, has developed an immune-based treatment that targets the toxic form of amyloid-beta, a protein that forms tiny fibers called plaques in the brains of Alzheimer’s sufferers. For more information, click here.
Immune-based therapy for Alzheimer’s moves closer to development
Feb 28, 2013